{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"110"}],"units":"Participants"}],"description":"Number of Participants With Shift From Baseline in Cardiac Imaging were reported.","groups":[{"description":"Participants received an oral dose of 45 mg of binimetinib tablets (3 tablets of 15 mg) twice daily in each cycle starting from Cycle 1 Day 1 (1 cycle =28 days) until disease progression, unacceptable toxicity, death, or discontinuation from the study treatment due to any other reason. Maximum treatment exposure was approximately of 19.4 months.","id":"OG000","title":"Binimetinib (MEK162)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Safety analysis set included all participants who received at least 1 dose of study treatment and had at least 1 post-baseline safety assessment.","reportingStatus":"POSTED","timeFrame":"From Baseline up to 30 days following the last dose of study treatment (maximum up to 21 months)","title":"Number of Participants With Shift From Baseline in Cardiac Imaging","type":"SECONDARY","unitOfMeasure":"Participants"}